<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.91008</article-id><article-id pub-id-type="publisher-id">ACM-28553</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190100000_54208576.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  重复经颅磁刺激联合草酸艾司西酞普兰对卒中后抑郁伴睡眠障碍的疗效观察
  Effect of Repeated Transcranial Magnetic Stimulation Combined with Oxalate Aisixitaipulan on Depression and Sleep Disturbance after Stroke
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>武</surname><given-names>军祥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>师</surname><given-names>宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>梦园</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>37</fpage><lpage>41</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨重复经颅磁刺激(Repeated transcranial magnetic stimulation rTMS)联合草酸艾司西酞普兰对卒中后抑郁(post-stroke depression PSD)伴睡眠障碍的疗效。方法：选取我院2017年12月至2018年11月被确诊为PSD伴睡眠障碍的患者100例，采用数字法随机分为两组，实验组50例，给予卒中常规治疗 + rTMS (连续刺激15 min/次，qd) + 草酸艾司西酞普兰。对照组50例，给予卒中常规治疗+草酸艾司西酞普兰。分别于治疗前后采用汉密顿抑郁量表(HAMD)、匹兹堡睡眠指数(PSQI)测评其症状改善情况。结果：经治疗，两组患者，HAMD、PSQI量表评分较治疗前均降低，p &lt; 0.05，具有统计学差异。结论：rTMS对PSD患者患者较好的改善抑郁水平，提高患者睡眠质量，对PSD抑郁及睡眠改善具有重要临床意义。
    Objective: To investigate the effect of repeated transcranial magnetic stimulation (repeated tran-scranial magnetic stimulation RTMS) combined with oxalic acid escitalopram phthalocyanine on post-stroke depression (post-stroke depression PSD) with sleep disorder. Methods: 100 patients who were diagnosed with PSD with sleep disorder from January 2018 to November 2018 were randomly divided into two groups by digital method, 50 cases in the experimental group, and +RTMS (continuous stimulation of 15 min/, QD) + oxalic acid escitalopram phthalic plane were given. In the control group, 50 cases were given routine treatment of stroke + oxalic acid escital-opram. The Hamilton Depression Scale (HAMD) and Pittsburg Sleep Index (PSQI) were used to evaluate the improvement of symptoms before and after treatment. Results: After treatment, the scores of the HAMD and PSQI scales were lower than those before treatment, p &lt; 0.05, with statis-tical difference. Conclusion: rTMS has significant clinical effect for PSD patients to improve their depression level and improve their sleep quality. 
  
 
</p></abstract><kwd-group><kwd>卒中后抑郁，重复经颅磁刺激(rTMS)，睡眠障碍，量表, Post-Stroke Depression</kwd><kwd> Repetitive Transcranial Magnetic Stimulation (rTMS)</kwd><kwd> Sleep Disorder</kwd><kwd> Scale</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>重复经颅磁刺激联合草酸艾司西酞普兰对卒中后抑郁伴睡眠障碍的疗效观察<sup> </sup></title><p>武军祥，师宁<sup>*</sup>，李梦园，刘杰</p><p>延安大学附属医院，陕西 延安</p><disp-formula id="hanspub.28553-formula70"><graphic xlink:href="//html.hanspub.org/file/8-1570780x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年10月24日；录用日期：2019年1月14日；发布日期：2019年1月21日</p><disp-formula id="hanspub.28553-formula71"><graphic xlink:href="//html.hanspub.org/file/8-1570780x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨重复经颅磁刺激(Repeated transcranial magnetic stimulation rTMS)联合草酸艾司西酞普兰对卒中后抑郁(post-stroke depression PSD)伴睡眠障碍的疗效。方法：选取我院2017年12月至2018年11月被确诊为PSD伴睡眠障碍的患者100例，采用数字法随机分为两组，实验组50例，给予卒中常规治疗 + rTMS (连续刺激15 min/次，qd) + 草酸艾司西酞普兰。对照组50例，给予卒中常规治疗+草酸艾司西酞普兰。分别于治疗前后采用汉密顿抑郁量表(HAMD)、匹兹堡睡眠指数(PSQI)测评其症状改善情况。结果：经治疗，两组患者，HAMD、PSQI量表评分较治疗前均降低，p &lt; 0.05，具有统计学差异。结论：rTMS对PSD患者患者较好的改善抑郁水平，提高患者睡眠质量，对PSD抑郁及睡眠改善具有重要临床意义。</p><p>关键词 :卒中后抑郁，重复经颅磁刺激(rTMS)，睡眠障碍，量表</p><disp-formula id="hanspub.28553-formula72"><graphic xlink:href="//html.hanspub.org/file/8-1570780x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-1570780x8_hanspub.png" /> <img src="//html.hanspub.org/file/8-1570780x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>随着全球老龄化的日趋严重，脑卒中仍然是世界卫生医疗不可忽视的重大问题，心脑血管疾病在我国为三大疾病死因之一，在美国为五大死因之一，据国外文献虽然脑卒中的发病率、流行率、死亡率、新复发率和残疾调整后的寿命年率有下降趋势，其归因于初级预防的有效推荐，但是脑卒中全球负担并非乐观 [<xref ref-type="bibr" rid="hanspub.28553-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.28553-ref2">2</xref>]，在病因学上，不仅要重视脑卒中在常规病因如高血压、高血脂等基础预防上，而且不可忽视如阻塞性睡眠呼吸暂停、电子烟等危险因素 [<xref ref-type="bibr" rid="hanspub.28553-ref3">3</xref>]。</p><p>脑卒中并发症如卒中后抑郁的发病率呈现逐年上升趋势，外文报道30%~35%脑卒中患者可在第一年内发生PSD [<xref ref-type="bibr" rid="hanspub.28553-ref4">4</xref>]，其主要为持久且显著的心境低落的临床表现，其可直接影响患者睡眠质量，严重影响患者的生活质量以及神经功能恢复。重复经颅磁刺激(rTMS)是一种安全、无创伤、无疼痛的新型治疗技术，对治疗心境障碍、帕金森等疾病，取得较好成果。且经美国FDA批准认证，rTMS为一种新型抗抑郁方法 [<xref ref-type="bibr" rid="hanspub.28553-ref5">5</xref>]。本研究通过对我院100例PSD患者对比分析，探讨重复经颅磁刺激联合草酸艾司西酞普兰对卒中后抑郁伴睡眠障碍的疗效。现将研究分析做如下报告。</p></sec><sec id="s4"><title>2. 临床方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取我院2017年12月至2018年11月被确诊为PSD伴睡眠障碍的患者100例，所有患者依入院先后顺序采用excel随机函数分为实验组和对照组，男性78例，女性22例，其中缺血性卒中80例，出血性卒中20例，文化水平：初中以下64例，高中21例，大专以上15例。两组患者在年龄、性别、病程、文化以及卒中类型无显著性差异，具有可比性。纳入研究一般资料如表1。</p></sec><sec id="s4_2"><title>2.2. 纳入标准和排出标准</title><p>纳入标准：1) 符合脑卒中诊断标准，并经头颅CT和MRI证实 [<xref ref-type="bibr" rid="hanspub.28553-ref6">6</xref>]；2) 符合国际疾病分类法ICD-10中抑郁症的诊断标准 [<xref ref-type="bibr" rid="hanspub.28553-ref7">7</xref>]；3) 年龄40~85周岁，首次发病；4) 病情稳定，依从性好，能完成配合；5) 遵循患者及家属自愿并签署知情同意书；6) 睡眠障碍符合《精神疾病诊断与统计手册》DSM-IV且PSQI &gt; 8分。排除标准：1) 不符合脑卒中诊断标准；2) 卒中前患有抑郁症；3) 复发性卒中；4) 心、肺、肝、肾功能不全和恶性高血压等其他限制活动的并发症；5) 存在严重认知及交流障碍无法配合者；6) 存在脑肿瘤等其他脑器质性疾病及既往精神异常者。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information included in the stud</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >男/女(例)</th><th align="center" valign="middle" >年龄( x &#175; &#177; s )</th><th align="center" valign="middle" >病程(月 x &#175; &#177; s )</th><th align="center" valign="middle" >卒中类型</th></tr></thead><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >32/18</td><td align="center" valign="middle" >63.23 &#177; 9.878</td><td align="center" valign="middle" >5.286 &#177; 1.420</td><td align="center" valign="middle" >缺血/出血28/12</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >35/15</td><td align="center" valign="middle" >63.32 &#177; 9.567</td><td align="center" valign="middle" >4.82 &#177; 1.369</td><td align="center" valign="middle" >缺血/出血42/8</td></tr></tbody></table></table-wrap><p>表1. 纳入研究的一般资料</p></sec><sec id="s4_3"><title>2.3. 研究方法</title><p>两组患者予常规治疗：缺血性卒中给予抗血小板聚集、控制血压、控制血糖等治疗，出血性卒中给予脱水降颅压、调整血压、防止继续出血等治疗。对照组：给予常规卒中治疗基础上 + 草酸艾司西酞普兰(山东京卫制药有限公司10 mg qd，晨服，共4周)；实验组：予常规卒中治疗 + 草酸艾司西酞普兰(山东京卫制药有限公司10 mg qd，晨服) + rTMS (南京伟思magneuro60，每次1200个脉冲，20个序列，连续刺激15 min/次，qd，部位选取右侧前额叶背外侧皮质，共4周)。该试验设计方案经医院伦理委员会批准且患者家属已签署知情同意书。</p></sec><sec id="s4_4"><title>2.4. 评定内容</title><p>量表评定由单一人员(不参与分组、治疗及统计)进行，于治疗前，第2周和第4周采用汉密尔顿抑郁量表(HAMD) [<xref ref-type="bibr" rid="hanspub.28553-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.28553-ref9">9</xref>] 评定抑郁程度，其从焦虑躯体化、体重、认知障碍、睡眠障碍等几个结构进行，低于7分无抑郁症状，超过17分为轻或中度抑郁，超过24分为严重抑郁，PSQI量表有着较好的可靠性和有效性，实现预期的效用，得分越高，表示睡眠质量越差 [<xref ref-type="bibr" rid="hanspub.28553-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.28553-ref11">11</xref>]。</p></sec><sec id="s4_5"><title>2.5. 统计方法</title><p>本研究为连续性计量资料，采用swilk-shapiro-wilk检验，服从正态分布，计量资料用均数 &#177; 标准差(x &#177; s)表示，进行配对样本t检验，鉴于评分高具有意义，以采用单侧p &lt; 0.05，表示差异有统计学意义，p &lt; 0.01表示差异具有显著性统计意义，二分类数据采用卡方检验，p &lt; 0.05，表示差异有统计学意义，所有统计分析均采用STATA15.0软件实现。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>两组患者治疗前HAMD和PSQI评分差异均无统计学意义(p &gt; 0.05)，于治疗第2周、第4周后HAMD评分较治疗前均显著改善(p &lt; 0.001)，而两组患者PSQI评分在第2周治疗后不具有统计学意义(p &gt; 0.05)，于第4周后具有统计学意义(p &lt; 0.05)。临床疗效评价：经治疗前后，两组总有效率经卡方检验无统计学意义(c<sup>2</sup> = 1.65, p &gt; 0.05)。两组患者在治疗中均出现不良反应，实验组出现头痛4例，嗜睡2例，头皮疼痛3例，且症状较轻，对照组出现头晕3例，嗜睡2例，胃不适3例，两组患者均在1周内缓减或消失，能继续配合进行，且两组间的生化检查无特殊异常。见表2，表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of HAMD and PSQI scores before and after treatment between the two groups ( x &#175; &#177; s scores</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  rowspan="2"  >治疗前</th><th align="center" valign="middle"  colspan="2"  >治疗后观察时间</th><th align="center" valign="middle"  rowspan="2"  >t</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >2周</td><td align="center" valign="middle" >4周</td></tr><tr><td align="center" valign="middle"  colspan="7"  >HAMD评分</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >16.06 &#177; 3.85</td><td align="center" valign="middle" >11.04 &#177; 2.55</td><td align="center" valign="middle" >4.94 &#177; 1.75</td><td align="center" valign="middle" >20.9952</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >15.86 &#177; 4.08</td><td align="center" valign="middle" >13.08 &#177; 2.86</td><td align="center" valign="middle" >9 &#177; 3.21</td><td align="center" valign="middle" >15.9356</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >0.5092</td><td align="center" valign="middle" >−5.9716</td><td align="center" valign="middle" >−9.1268</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.6129</td><td align="center" valign="middle" >0.0000</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle"  colspan="7"  >PSQI评分</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >14.28 &#177; 3.45</td><td align="center" valign="middle" >10.64 &#177; 2.79</td><td align="center" valign="middle" >6.36 &#177; 2.27</td><td align="center" valign="middle" >18.9135</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >14.06 &#177; 3.01</td><td align="center" valign="middle" >11.12 &#177; 2.08</td><td align="center" valign="middle" >7.37 &#177; 2.36</td><td align="center" valign="middle" >14.8697</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >0.3593</td><td align="center" valign="middle" >−1.8196</td><td align="center" valign="middle" >−2.5504</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.7209</td><td align="center" valign="middle" >0.0749</td><td align="center" valign="middle" >0.0139</td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗前后HAMD和PSQI评分比较( x &#175; &#177; s )</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Effectiveness of two groups of patients after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  colspan="4"  >疗效程度</th><th align="center" valign="middle"  rowspan="2"  >总有效率</th></tr></thead><tr><td align="center" valign="middle" >痊愈</td><td align="center" valign="middle" >显著有效</td><td align="center" valign="middle" >有效</td><td align="center" valign="middle" >无效</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >22 (44%)</td><td align="center" valign="middle" >15 (30%)</td><td align="center" valign="middle" >11 (22%)</td><td align="center" valign="middle" >6 (12%)</td><td align="center" valign="middle" >88%</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >21 (42%)</td><td align="center" valign="middle" >10 (20%)</td><td align="center" valign="middle" >9 (18%)</td><td align="center" valign="middle" >10 (10%)</td><td align="center" valign="middle" >80%</td></tr></tbody></table></table-wrap><p>表3. 两组患者治疗后的有效率</p><p>注：p &gt; 0.05。</p></sec><sec id="s6"><title>4. 讨论</title><p>随着老龄化的不断上升，脑血管疾病的发病率虽有下降趋势，但是卒中后并发症如卒中后抑郁却呈现增长状态 [<xref ref-type="bibr" rid="hanspub.28553-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.28553-ref2">2</xref>]。PSD伴随一系列情感及心境障碍在一定程度上可增加器质性改变的风险 [<xref ref-type="bibr" rid="hanspub.28553-ref12">12</xref>]，严重影响卒中患者的预后和生命质量，甚至给国家医疗带来巨大负担，有效的预防和治疗PSD是毋庸置疑的举措，草酸艾司西酞普兰作为一种选择性5-HT再摄取抑制剂，主用于抑郁症和焦虑症的治疗，此药对血清转运具有高度选择性、强效的抑制性作用，增强神经递质在中枢的活性能力 [<xref ref-type="bibr" rid="hanspub.28553-ref13">13</xref>]，据外文报道，对115例PSD患者研究发现，此药能显著降低PSD的症状(p &lt; 0.01) [<xref ref-type="bibr" rid="hanspub.28553-ref14">14</xref>]，据Pollack M研究发现此药可显著改善睡眠和日间功能，且没有耐受性，但是会有不适感、头痛和嗜睡能并发症 [<xref ref-type="bibr" rid="hanspub.28553-ref15">15</xref>]。rTMS作为一种新型的辅助治疗手段备受欢迎，尤其在精神及神经领域的治疗，据有关研究，rTMS能提高神经分泌、神经纤维再生和可塑性、神经递质受体水平，改善脑灌注、血脑屏障，但荟萃分析缺乏一致性 [<xref ref-type="bibr" rid="hanspub.28553-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.28553-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.28553-ref18">18</xref>]。且其可引起癫痫发作、晕厥、低体位性血压、头皮痛等并发症。据刘超猛等meta分析rTMS能有效改善PSD的神经功能恢复、抑郁状态(p &lt; 0.00001)等症状 [<xref ref-type="bibr" rid="hanspub.28553-ref19">19</xref>]，而Cohen DA研究rTMS能显著增强睡眠-觉醒及与周围环境调节的可塑性 [<xref ref-type="bibr" rid="hanspub.28553-ref20">20</xref>]。药物治疗PSD患者的耐受性、不良反应、依从性在一定程度上不可避免，甚至恶化，加重病情，而rTMS的优势在某种程度上能弥补药物治疗上的缺陷，二者相辅相成不乏为一种有效的治疗举措，对临床工作起到一定的帮助和提示作用。本研究样本量小，观察时间较短，结论有待大数据进一步验证。</p></sec><sec id="s7"><title>文章引用</title><p>武军祥,师 宁,李梦园,刘 杰. 重复经颅磁刺激联合草酸艾司西酞普兰对卒中后抑郁伴睡眠障碍的疗效观察 Effect of Repeated Transcranial Magnetic Stimulation Combined with Oxalate Aisixitaipulan on Depression and Sleep Disturbance after Stroke[J]. 临床医学进展, 2019, 09(01): 37-41. https://doi.org/10.12677/ACM.2019.91008</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28553-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Feigin, V.L., Norrving, B. and Mensah, G.A. (2017) Global Burden of Stroke. Circulation Research, 120, 439-448.  
&lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.116.308413</mixed-citation></ref><ref id="hanspub.28553-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hankey, G.J. (2017) Stroke. Lancet, 389, 641-654. &lt;br&gt;https://doi.org/10.1016/S0140-6736(16)30962-X</mixed-citation></ref><ref id="hanspub.28553-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Guzik, A. and Bushnell, C. (2017) Stroke Epidemiology and Risk Factor Management. Continuum (Minneap Minn), 23, 15-39.</mixed-citation></ref><ref id="hanspub.28553-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, R.G. and Jorge, R.E. (2016) Post-Stroke Depression: A Review. American Journal of Psychiatry, 173, 221-231. &lt;br&gt;https://doi.org/10.1176/appi.ajp.2015.15030363</mixed-citation></ref><ref id="hanspub.28553-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">O’Reardon, J.P., Solvason, H.B., Janicak, P.G., et al. (2007) Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry, 62, 1208-1216. &lt;br&gt;https://doi.org/10.1016/j.biopsych.2007.01.018</mixed-citation></ref><ref id="hanspub.28553-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华神经科学会, 中华神经外科学会. 各类脑血管病诊断要点[J]. 中华神经科杂志, 1996, 29(6): 379-380.</mixed-citation></ref><ref id="hanspub.28553-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">范肖冬. ICD-10精神与行为障碍分类[J]. 北京: 人民卫生出版社, 1993: 70-79.</mixed-citation></ref><ref id="hanspub.28553-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Graessel, E., Viegas, R., Stemmer, R., et al. (2009) The Erlangen Test of Activities of Daily Living: First Results on Reliability and Validity of a Short Performance Test to Measure Fundamental Activities of Daily Living in Dementia Patients. International Psychogeriatrics, 21, 103-112. &lt;br&gt;https://doi.org/10.1017/S1041610208007710</mixed-citation></ref><ref id="hanspub.28553-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">季洁, 张樟进, 赵红. 评价卒中后抑郁常用量表分析[J]. 中华针灸电子杂志, 2017, 6(3): 120-123.</mixed-citation></ref><ref id="hanspub.28553-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mollayeva, T., Thurairajah, P., Burton, K., Mollayeva, S., Shapiro, C.M. and Colantonio, A. (2016) The Pittsburgh Sleep Quality Index as a Screening Tool for Sleep Dysfunction in Clinical and Non-Clinical Samples: A Systematic Review and Meta-Analysis. Sleep Medicine Reviews, 25, 52-73. &lt;br&gt;https://doi.org/10.1016/j.smrv.2015.01.009</mixed-citation></ref><ref id="hanspub.28553-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">张理义, 孔令明, 张其军, 陶凤燕, 马爱国, 刘云, 高玉芳, 涂德华, 苏为吉, 王丽杰. 中国睡眠障碍量表的研制及信效度检验[J]. 世界睡眠医学杂志, 2014, 1(3): 140-146.</mixed-citation></ref><ref id="hanspub.28553-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Liston, C., Chen, A.C., Zebley, B.D., et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biological Psychiatry, 76, 517-526. &lt;br&gt;https://doi.org/10.1016/j.biopsych.2014.01.023</mixed-citation></ref><ref id="hanspub.28553-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kirino, E. (2012) Escitalopram for the Management of Major Depressive Disorder: A Review of Its Efficacy, Safety, and Patient Acceptability. Patient Prefer Adherence. &lt;br&gt;https://doi.org/10.2147/PPA.S22495</mixed-citation></ref><ref id="hanspub.28553-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J.H. and Jiang, P. (2018) Efficacy of Escitalopram Oxalate for Pa-tients with Post-Stroke Depression. Medicine (Baltimore), 97, e0219. &lt;br&gt;https://doi.org/10.1097/MD.0000000000010219</mixed-citation></ref><ref id="hanspub.28553-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Pollack, M., Kinrys, G., Krystal, A., et al. (2008) Eszopi-clone Coadministered with Escitalopram in Patients with Insomnia and Comorbid Generalized Anxiety Disorder. Ar-chives of General Psychiatry, 65, 551-562.  
&lt;br&gt;https://doi.org/10.1001/archpsyc.65.5.551</mixed-citation></ref><ref id="hanspub.28553-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nahas, Z., DeBrux, C., Chandler, V., et al. (2000) Lack of Signif-icant Changes on Magnetic Resonance Scans before and after 2 Weeks of Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Depression. The Journal of ECT, 16, 380-390. &lt;br&gt;https://doi.org/10.1097/00124509-200012000-00008</mixed-citation></ref><ref id="hanspub.28553-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Michael, N., Gosling, M., Reutemann, M., et al. (2003) Metabolic Changes after Repetitive Transcranial Magnetic Stimulation (rTMS) of the Left Prefrontal Cortex: A Sham-Controlled Proton Magnetic Resonance Spectroscopy (1HMRS) Study of Healthy Brain. European Journal of Neuroscience, 17, 2462-2468.  
&lt;br&gt;https://doi.org/10.1046/j.1460-9568.2003.02683.x</mixed-citation></ref><ref id="hanspub.28553-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hausmann, A., Weis, C., Marksteiner, J., et al. (2000) Chronic Repetitive Transcranial Magnetic Stimulation Enhances c-fos in the PARIETAL cortex and Hippocampus. Brain Res Mol Brain Res, 769, 355-362.</mixed-citation></ref><ref id="hanspub.28553-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘超猛, 王梅子, 张桂青. 重复经颅磁刺激治疗脑卒中后抑郁效果的Meta分析[J]. 华西医学, 2018(10): 1-8.</mixed-citation></ref><ref id="hanspub.28553-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, D.A., Freitas, C., Tormos, J.M., Oberman, L., Eldaief, M. and Pascual-Leone, A. (2010) Enhancing Plasticity through Repeated rTMS Sessions: The Benefits of a Night of Sleep. Clinical Neurophysiology, 121, 2159-2164.  
&lt;br&gt;https://doi.org/10.1016/j.clinph.2010.05.019</mixed-citation></ref></ref-list></back></article>